{
  "title": "Monoclonal Antibodies Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)",
  "slug": "monoclonal-antibodies-market",
  "industry": "Pharmaceuticals & Therapeutics",
  "parent_industry": "Healthcare (Pharma, Medical Devices, Biotech)",
  "url": "https://www.mordorintelligence.com/industry-reports/monoclonal-antibodies-market",
  "scraped_at": "2026-09-17T17:43:19+07:00",
  "dataset_properties": [
    {
      "@type": "PropertyValue",
      "name": "Market Size (2026)",
      "value": 323.89,
      "unitText": "USD Billion"
    },
    {
      "@type": "PropertyValue",
      "name": "Market Size (2031)",
      "value": 596.12,
      "unitText": "USD Billion"
    },
    {
      "@type": "PropertyValue",
      "name": "Growth Rate (2026 - 2031)",
      "value": 12.99,
      "unitText": "PERCENT"
    },
    {
      "@type": "PropertyValue",
      "name": "Fastest Growing Market",
      "value": "Asia Pacific"
    },
    {
      "@type": "PropertyValue",
      "name": "Largest Market",
      "value": "North America"
    },
    {
      "@type": "PropertyValue",
      "name": "Market Concentration",
      "value": "Medium"
    }
  ],
  "faq": [
    {
      "@type": "Question",
      "name": "What is the current size of the global monoclonal antibodies market?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "The market stood at USD 323.89 billion in 2026 and is forecast to climb to USD 596.12 billion by 2031."
      }
    },
    {
      "@type": "Question",
      "name": "Which therapeutic area contributes the largest share of monoclonal antibody revenues?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Oncology applications generated 49.35% of global revenue in 2025, making it the leading indication."
      }
    },
    {
      "@type": "Question",
      "name": "Which segment is projected to grow the fastest through 2031?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Autoimmune diseases are expected to post the strongest 19.22% CAGR, outpacing all other indications."
      }
    },
    {
      "@type": "Question",
      "name": "How quickly are humanized antibodies expanding?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Humanized variants are advancing at an 18.02% CAGR, the fastest rate among source categories."
      }
    },
    {
      "@type": "Question",
      "name": "Why are specialty and ambulatory centers gaining importance?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Subcutaneous formulations such as Tecentriq Hybrenza cut chair time to about seven minutes, enabling convenient outpatient or at-home administration and driving a 15.98% CAGR for these centers."
      }
    }
  ],
  "images": [
    "images/monoclonal-antibodies-market-size.png",
    "images/monoclonal-antibodies-market-major-players.png",
    "images/monoclonal-antibodies-market-share-by-production-method.png",
    "images/monoclonal-antibodies-market-share-by-indication.png",
    "images/monoclonal-antibodies-market-growth-rate-by-region.png",
    "images/monoclonal-antibodies-market-competitive-landscape-market-concentration.png",
    "images/market-snapshot.png",
    "images/pdf3.png",
    "images/Esomar-25.png",
    "images/GPTW-25-3xl.png",
    "images/monoclonal-antibodies-market-size.png"
  ],
  "sections_count": 13
}